Abstract:The hybrid antibacterial peptide CA–MA [cecropinA(1-8)–magainin2(1-12)] with potent antimicrobial properties but no hemolytic activity is a potential alternative antibiotic. To explore a new approach for high-level expression of the hybrid peptide CA–MA in Escherichia coli, the sequence of ubiquitin (UBI) from housefly was inserted into the plasmid pQE30 to construct the vector pQEUBI. The cDNA fragment encoding CA–MA with preferred codons of E. coli was obtained by recursive PCR (rPCR) and cloned into the vector pQEUBI to express the fusion protein (His)6-UBI-CA–MA. The fusion protein was expressed in soluble form under the optimized conditions at high level (more than 36% of the total proteins). With (His)6-tag, the fusion protein was easily purified by Ni–NTA chromatography and 36mg of fusion protein was purified from 1L of culture medium. The fusion protein was efficiently cleaved by ubiquitin C-terminal hydrolase (UCH), yielding recombinant CA–MA with high antimicrobial activity. After removing the contaminants by Ni–NTA chromatography, recombinant CA–MA was purified to homogeneity by reversed-phase HPLC and 6.8mg of pure active CA–MA was obtained from 1L culture medium. Analysis of recombinant CA–MA by MALDI-TOF-MS showed that the molecular weight of the purified recombinant CA–MA was 2559Da, which perfectly matches the mass (2559Da) calculated from the amino acid sequence. Analysis of CA–MA by circular dichroism (CD) revealed that the secondary structures of CA–MA in water solution were 17.4% α-helix and 82.6% random coil but no β-sheet. Our results demonstrated that functional CA–MA can be produced in sufficient quantities using the ubiquitin fusion technique. This is the first report on the heterologous expression of a hybrid antibacterial peptide fused to ubiquitin in E. coli.

High-level expression of the recombinant hybrid peptide cecropinA(1-8)-magainin2(1-12) with an ubiquitin fusion partner in Escherichia coli.

Design and high-level expression of a hybrid antimicrobial peptide LF15-CA8 in Escherichia coli

Recombinant expression of a novel antimicrobial peptide consisting of human α-defensin 5 and Mytilus coruscus mytilin-1 in Escherichia coli

Expressing Antimicrobial Peptide Cathelicidin-Bf in Bacillus Subtilis Using Sumo Technology

High-level SUMO-mediated Fusion Expression of ABP-dHC-cecropin A from Multiple Joined Genes in Escherichia Coli.

Recombinant Expression of Antimicrobial Peptides Using a Novel Self-Cleaving Aggregation Tag Inescherichia Coli

[Acute salpingitis and contraceptive methods].

Soluble fusion expression and characterization of bioactive human beta-defensin 26 and 27

Expression of Hybrid Peptide EF-1 in Pichia pastoris, Its Purification, and Antimicrobial Characterization

Screening and heterologous expression of an antimicrobial peptide SCAK33 with broad-spectrum antimicrobial activity resourced from sea cucumber proteome

Extracellular production of Ulp1403-621 in leaky E. coli and its application in antimicrobial peptide production

Hybridization with Insect Cecropin A (1–8) Improve the Stability and Selectivity of Naturally Occurring Peptides

Application of Engineered Carrot Antifreeze Protein in the Cryopreservation of Rice Cells by Adsorbing into Ice surface to Inhibit Recrystallization

Design, expression, and characterization of a novel cecropin A-derived peptide with high antibacterial activity

Soluble Expression of Antimicrobial Peptide BSN-37 from Escherichia coli by SUMO Fusion Technology

Enhanced Expression and Primary Purification of Soluble HBD3 Fusion Protein in Escherichia coli

Expression of the Antimicrobial Peptide SE-33-A2P, a Modified Analog of Cathelicidin, and an Analysis of Its Properties

Expression and Purification of Two Different Antimicrobial Peptides, PR-39 and Protegrin-1 in Escherichia Coli.

Expression and Purification of Antimicrobial Peptide AP2 Using SUMO Fusion Partner Technology Inescherichia Coli

High-yield recombinant expression of the chicken antimicrobial peptide fowlicidin-2 in Escherichia coli.

Recombinant expression, purification, and antimicrobial activity of a novel hybrid antimicrobial peptide LFT33